| 臺大學術典藏 |
2022-09-09T04:21:25Z |
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis
|
You H.; Ma X.; Efe C.; Wang G.; Jeong S.-H.; Abe K.; Duan W.; Chen S.; Kong Y.; Zhang D.; Wei L.; Wang F.-S.; Lin H.-C.; Yang J.M.; Tanwandee T.; Gani R.A.; Payawal D.A.; Sharma B.C.; Hou J.; Yokosuka O.; Dokmeci A.K.; Crawford D.; JIA-HORNG KAO; Piratvisuth T.; Suh D.J.; Lesmana L.A.; Sollano J.; Lau G.; Sarin S.K.; Omata M.; Tanaka A.; Jia J. |
| 臺大學術典藏 |
2022-09-09T04:21:24Z |
Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine
|
Park J.; Le A.K.; Tseng T.-C.; Yeh M.-L.; Jun D.W.; Trinh H.; Wong G.L.H.; Chen C.-H.; Peng C.-Y.; Kim S.E.; Oh H.; Kwak M.-S.; Cheung K.S.; Toyoda H.; Hsu Y.-C.; Jeong J.Y.; Yoon E.L.; Ungtrakul T.; Zhang J.; Xie Q.; Ahn S.B.; Enomoto M.; Shim J.-J.; Cunningham C.; Jeong S.W.; Cho Y.K.; Ogawa E.; Huang R.; Lee D.-H.; Takahashi H.; Tsai P.-C.; Huang C.-F.; Dai C.-Y.; Tseng C.-H.; Yasuda S.; Kozuka R.; Li J.; Wong C.; Wong C.C.; Zhao C.; Hoang J.; Eguchi Y.; Wu C.; Tanaka Y.; Gane E.; Tanwandee T.; Cheung R.; Yuen M.-F.; Lee H.-S.; Yu M.-L.; JIA-HORNG KAO; Yang H.-I.; Nguyen M.H. |
| 臺大學術典藏 |
2022-06-10T06:10:59Z |
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
|
Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T. |
| 臺大學術典藏 |
2022-01-24T09:32:01Z |
Patterns of managing chronic hepatitis B treatment-related drug resistance: A survey of physicians in Mainland China, South Korea, Taiwan, and Thailand
|
Chainuvati S.; Cheng J.; Hou J.L.; Hsu C.W.; Jia J.D.; Komolmit P.; Kwon S.Y.; Lee C.H.; Li H.; Li Y.; CHUN-JEN LIU; Neo B.L.; Peng C.Y.; Tanwandee T.; Wongcharatrawee S.; Wu J.C.; Yu M.L.; Zhang X.X. |
| 臺大學術典藏 |
2021-09-04T06:12:12Z |
Entecavir: A review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease
|
Keating G.M.; Buti M.; Gadano A.; JIA-HORNG KAO; Lee C.-M.; Peng C.-Y.; Schiff E.R.; Tanwandee T. |
| 臺大學術典藏 |
2021-09-04T06:11:10Z |
Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis
|
JIA-HORNG KAO; Tung S.-Y.; Lee Y.; Thongsawat S.; Tanwandee T.; Sheen I.-S.; Wu J.J.; Li H.; Brennan B.J.; Zhou J.; Le Pogam S.; Najera I.; Thommes J.A.; Hill G. |
| 臺大學術典藏 |
2021-09-04T05:16:54Z |
Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis
|
Yeo Y.H.; Ho H.J.; Yang H.-I.; Tseng T.-C.; Hosaka T.; Trinh H.N.; Kwak M.-S.; Park Y.M.; Fung J.Y.Y.; Buti M.; Rodr?guez M.; Treeprasertsuk S.; Preda C.M.; Ungtrakul T.; Charatcharoenwitthaya P.; Li X.; Li J.; Zhang J.; Le M.H.; Wei B.; Zou B.; Le A.; Jeong D.; Chien N.; Kam L.; Lee C.-C.; Riveiro-Barciela M.; Istratescu D.; Sriprayoon T.; Chong Y.; Tanwandee T.; Kobayashi M.; Suzuki F.; Yuen M.-F.; Lee H.-S.; JIA-HORNG KAO; Lok A.S.; Wu C.-Y.; Nguyen M.H. |
| 臺大學術典藏 |
2021-09-04T05:16:30Z |
Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients
|
Yeo Y.H.; Tseng T.-C.; Hosaka T.; Cunningham C.; Fung J.Y.Y.; Ho H.J.; Kwak M.-S.; Trinh H.N.; Ungtrakul T.; Yu M.-L.; Kobayashi M.; Le A.K.; Henry L.; Li J.; Zhang J.; Sriprayoon T.; Jeong D.; Tanwandee T.; Gane E.; Cheung R.C.; Wu C.-Y.; Lok A.S.; Lee H.-S.; Suzuki F.; Yuen M.-F.; JIA-HORNG KAO; Yang H.-I.; Nguyen M.H. |
| 臺大學術典藏 |
2021-09-04T05:16:25Z |
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
|
Eslam M.; Sarin S.K.; Wong V.W.-S.; Fan J.-G.; Kawaguchi T.; Ahn S.H.; Zheng M.-H.; Shiha G.; Yilmaz Y.; Gani R.; Alam S.; Dan Y.Y.; JIA-HORNG KAO; Hamid S.; Cua I.H.; Chan W.-K.; Payawal D.; Tan S.-S.; Tanwandee T.; Adams L.A.; Kumar M.; Omata M.; George J. |
| 臺大學術典藏 |
2021-09-04T05:16:20Z |
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients
|
Liu M.; Tseng T.-C.; Jun D.W.; Yeh M.-L.; Trinh H.; Wong G.L.H.; Chen C.-H.; Peng C.-Y.; Kim S.E.; Oh H.; Kwak M.-S.; Cheung M.; Toyoda H.; Hsu Y.-C.; Jeong J.Y.; Yoon E.L.; Ungtrakul T.; Zhang J.; Xie Q.; Ahn S.B.; Enomoto M.; Shim J.-J.; Cunningham C.; Jeong S.W.; Cho Y.K.; Ogawa E.; Huang R.; Lee D.-H.; Takahashi H.; Tsai P.-C.; Huang C.-F.; Dai C.-Y.; Tseng C.-H.; Yasuda S.; Kozuka R.; Li J.; Wong C.; Wong C.C.; Zhao C.; Hoang J.; Eguchi Y.; Wu C.; Tanaka Y.; Gane E.; Tanwandee T.; Cheung R.; Yuen M.-F.; Lee H.-S.; Yu M.-L.; JIA-HORNG KAO; Yang H.-I.; Nguyen M.H. |
| 臺大學術典藏 |
2021-09-01T01:53:51Z |
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)
|
Park J.-W.; Amarapurkar D.; Chao Y.; Chen P.-J.; Geschwind J.-F.H.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:42Z |
Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel
|
ANN-LII CHENG; Amarapurkar D.; Chao Y.; Chen P.-J.; Geschwind J.-F.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Park J.-W. |
| 臺大學術典藏 |
2021-08-11T03:46:38Z |
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
|
Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T. |
| 臺大學術典藏 |
2021-07-03T03:34:19Z |
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)
|
Park J.-W.; Amarapurkar D.; Chao Y.; PEI-JER CHEN; Geschwind J.-F.H.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:14Z |
Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel
|
Cheng A.L.; Amarapurkar D.; Chao Y.; PEI-JER CHEN; Geschwind J.-F.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Park J.-W. |
| 臺大學術典藏 |
2021-07-03T03:34:05Z |
Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection
|
Colvin R.A.; Tanwandee T.; Piratvisuth T.; Thongsawat S.; Hui A.J.; Zhang H.; Ren H.; PEI-JER CHEN; Chuang W.-L.; Sobhonslidsuk A.; Li R.; Qi Y.; Praestgaard J.; Han Y.; Xu J.; Stein D.S.; Chien R.-N.; Flisiak R.; Jablkowski M.; Liaw Y.-F.; Sung J.J.-Y. |
| 臺大學術典藏 |
2021-07-03T03:33:50Z |
Management of hepatitis C virus infection in the Asia-Pacific region: an update
|
Lim S.G.; Aghemo A.; PEI-JER CHEN; Dan Y.Y.; Gane E.; Gani R.; Gish R.G.; Guan R.; Jia J.D.; Lim K.; Piratvisuth T.; Shah S.; Shiffman M.L.; Tacke F.; Tan S.S.; Tanwandee T.; Win K.M.; Yurdaydin C. |
| 臺大學術典藏 |
2021-02-02T07:51:01Z |
Lamivudine for patients with chronic hepatitis B and advanced liver disease
|
Liaw Y.-F.; Sung J.J.Y.; Chow W.C.; Farrell G.; Lee, Cha-Ze; Yuen H.; Tanwandee T.; Tao Q.-M.; Shue K.; Keene O.N.; Dixon J.S.; Gray D.F.; Sabbat J. |
| 臺大學術典藏 |
2018-09-10T08:44:43Z |
Entecavir: A review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease
|
Keating, G.M.; Buti, M.; Gadano, A. ;Kao, J.-H. ;Lee, C.-M.; Peng, C.-Y.; Schiff, E.R.; Tanwandee, T.; JIA-HORNG KAO |
| 高雄醫學大學 |
2013 |
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
|
GR*, Foster;Zeuzem, S;Pianko, S;Sarin, SK;Piratvisuth, T;Shah, S;Andreone, P;Sood, A;莊萬龍;Lee, CM;George, J;Gould, M;Flisiak, R;Jacobson, IM;Komolmit, P;Thongsawat, S;Tanwandee, T;Rasenack, J;Sola, R;Messina, I;Yin, Y;Cammarata, S;Feutren, G;Brown, KK. ; Foster, GR;Zeuzem, S;Pianko, S;Sarin, SK;Piratvisuth, T;Shah, S;Andreone, P;Sood, A;Chuang, WL;Lee, CM;George, J;Gould, M;Flisiak, R;Jacobson, IM;Komolmit, P;Thongsawat, S;Tanwandee, T;Rasenack, J;Sola, R;Messina, I;Yin, Y;Cammarata, S;Feutren, G;Brown, KK. |
| 國家衛生研究院 |
2012-05-20 |
Randomized phase II trial of TACE plus everolimus as first-line therapy in localized unresectable hepatocellular carcinoma (HCC): The TRACER trial
|
Poon, RTP;Chen, LT;Xue, HL;Tannir, B;Wang, JH;Tanwandee, T;Paik, SW |
| 高雄醫學大學 |
2011 |
Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients.
|
莊萬龍; Patel K;Thompson AJ;Chuang WL;Lee CM;Peng CY;Shanmuganathan G;Thongsawat S;Tanwandee T;Mahachai V;Pramoolsinsap C;Cho M;Han KH;Shah SR;Foster GR;Clark PJ;Pulkstenis E;Subramanian GM;McHutchison JG. |
| 高雄醫學大學 |
2011 |
Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.
|
廖運範(長庚)莊萬龍; Liaw YF;Jia JD;Chan HL;Han KH;Tanwandee T;Chuang WL;Tan DM;Chen XY;Gane E;Piratvisuth T;Chen L;Xie Q;Sung JJ;Wat C;Bernaards C;Cui Y;Marcellin P. |
| 國立成功大學 |
2009-10 |
Long-term entecavir (ETV) therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in patients with HBeAg positive and negative chronic hepatitis B (CHB): results from studies ETV-022,-027 and-901
|
Chang, Ting-Tsung; Wu, S. S.; Chao, Y. C.; Han, K. H.; Yoon, S. K.; Lai, C. L.; Akbar, N.; Liaw, Y. F.; Tanwandee, T.; Goodman, Z. D.; Zhang, H.; Hindes, R.; Iloeje, U.; Beebe, S.; Kreter, B. |
| 國立成功大學 |
2009-10 |
Long-term entecavir therapy improves fibrosis/cirrhosis and results in continued histologic improvement in CHB
|
Chang, Ting-Tsung; Wu, S. S.; Chao, Y. C.; Han, K. H.; Yoon, S. K.; Lai, C. L.; Akbar, N.; Liaw, Y. F.; Tanwandee, T.; Munafo, L.; Newman, J.; Slade, P.; Goodman, Z. D.; Zhang, H.; Hindes, R.; Iloeje, U.; Beebe, S.; Kreter, B. |
| 高雄醫學大學 |
2009 |
Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China; South Korea; Taiwan; and Thailand.
|
余明隆; Chainuvati S;Cheng J;Hou JL;Hsu CW;Jia JD;Komolmit P;Kwon SY;Lee CH;Li H;Li Y;Liu CJ;Neo BL;Peng CY;Tanwandee T;Wongcharatrawee S;Wu JC;Yu ML;Zhang XX. |
